News & Analysis on Clinical Trial Services & Contract Research And Development
By Natalie Morrison
- Last updated on
Deal comes to the technology CRO from her role as immunology PRO lead at Janssen Pharma – a division of Johnson & Johnson.
Jeffrey Litwin MD, president and CEO of ERT said: "Having worked inside sponsor organizations and across a number of entities within the PRO community, Linda brings insight and perspective on the creation and implementation of Patient, Clinician and Observer reported outcomes.
Her domain knowledge will enable her to add considerable value to ERT's offerings and to our clients."